Research progress on immune checkpoint inhibitors therapy for non-small cell lung cancer with positive driver gene
-
摘要:
非小细胞肺癌(NSCLC)是中国肺癌最常见的病理分型。随着精准医疗的发展，靶向治疗和免疫治疗被广泛应用于恶性肿瘤患者的治疗中，并极大地改善了患者的预后和生存周期。大部分NSCLC患者存在驱动基因突变。以程序性死亡分子-1(PD-1)/程序性死亡因子配体-1(PD-L1)抗体为代表的免疫检查点抑制剂(ICIs)在驱动基因阴性晚期NSCLC患者中取得良好的临床效果，且在部分情况下可作为一线及二线治疗的标准方案。但ICIs治疗在驱动基因阳性NSCLC患者中的应用仍存在争议。本研究对驱动基因阳性NSCLC的免疫特征进行分析，并就ICIs治疗对驱动基因阳性NSCLC患者的应用效果进行综述。
Abstract:The most common pathological type of lung cancer in China is non-small cell lung cancer (NSCLC). With the development of precision medicine, targeted therapy and immunotherapy are widely used in the treatment of patients with malignant tumors, and greatly improve the prognosis and survival cycle of patients. Most of NSCLC patients have driver gene mutations. Immune checkpoint inhibitors (ICIs), represented by programmed death molecule-1 (PD-1)/programmed death factor ligand 1 (PD-L1) antibodies, have achieved good clinical results in treating advanced NSCLC patients with negative driver genes, and in some cases, it can be used as a standard regimen for first line and second line treatments. However, the application of ICIs therapy in NSCLC patients with positive driver genes is still controversial. This study analyzed the immune characteristics of NSCLC patients with positive driver gene and reviewed the application effect of ICIs therapy in treating NSCLC patients with positive driver genes.
-
-
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] 张伟杰, 张若琛, 陈义坤, 等. 甲基双加氧酶对非小细胞肺癌增殖、迁移和侵袭的影响及机制[J]. 实用临床医药杂志, 2021, 25(10): 24-28, 32. doi: 10.7619/jcmp.20211711 [3] 周彩存, 王洁, 步宏, 等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版)[J]. 中国肺癌杂志, 2020, 23(2): 65-76. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ202002001.htm [4] SILVA M D, ITCHINS M, PAVLAKIS N. Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition[J]. Ann Transl Med, 2020, 8(8): 555. doi: 10.21037/atm.2020.01.87
[5] 李洋, 蒋立峰, 孙旭, 等. 免疫检查点抑制剂在表皮生长因子受体突变非小细胞肺癌中的研究进展[J]. 实用临床医药杂志, 2022, 26(2): 142-148. doi: 10.7619/jcmp.20214607 [6] 朱金秀, 谢强, 钟爱虹, 等. 安罗替尼一线治疗驱动基因阴性老年肺腺癌患者的疗效和预后分析[J]. 中国新药与临床杂志, 2021, 40(6): 441-446. doi: 10.14109/j.cnki.xyylc.2021.06.09 [7] HOWLADER N, FORJAZ G, MOORADIAN M J, et al. The effect of advances in lung-cancer treatment on population mortality[J]. N Engl J Med, 2020, 383(7): 640-649. doi: 10.1056/NEJMoa1916623
[8] MAZIERES J, DRILON A, LUSQUE A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry[J]. Ann Oncol, 2019, 30(8): 1321-1328. doi: 10.1093/annonc/mdz167
[9] BALDACCI S, GRÉGOIRE V, PATRUCCO E, et al. Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma[J]. Lung Cancer, 2020, 146: 366-369. doi: 10.1016/j.lungcan.2020.05.008
[10] 李语馨, 张乐蒙, 陈建华. 免疫检查点抑制剂治疗驱动基因阳性晚期非小细胞肺癌的研究进展[J]. 中南大学学报: 医学版, 2020, 45(4): 418-425. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202004011.htm [11] PAKKALA S, RAMALINGAM S S. Personalized therapy for lung cancer: striking a moving target[J]. JCI Insight, 2018, 3(15): e120858. doi: 10.1172/jci.insight.120858
[12] 杨荣, 廖晓阳, 雷弋, 等. 早期肺腺癌中关键驱动基因及抑癌基因的研究进展[J]. 中国全科医学, 2021, 24(29): 3774-3780. doi: 10.12114/j.issn.1007-9572.2021.00.542 [13] 赵冉, 伍潇怡, 陈颖玮, 等. 二代测序技术检测650例非小细胞肺癌驱动基因突变[J]. 临床与实验病理学杂志, 2022, 38(2): 152-156. https://www.cnki.com.cn/Article/CJFDTOTAL-LSBL202202005.htm [14] 高鸣, 周清, 吴一龙. 免疫时代下不可手术Ⅲ期非小细胞肺癌治疗变革[J]. 循证医学, 2022, 22(1): 1-3, 29. https://www.cnki.com.cn/Article/CJFDTOTAL-YEBM202201001.htm [15] 马淑香, 马楠, 韩晶, 等. 不同驱动基因突变晚期非小细胞肺癌患者免疫治疗疗效及预后影响因素分析[J]. 中华医学杂志, 2022, 102(13): 922-929. doi: 10.3760/cma.j.cn112137-20211025-02352 [16] 黄亚, 张西志. 非小细胞肺癌综合治疗中的放疗联合免疫治疗[J]. 实用临床医药杂志, 2019, 23(14): 7-11. doi: 10.7619/jcmp.201914002 [17] PARK K, VANSTEENKISTE J, LEE K H, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS[J]. Ann Oncol, 2020, 31(2): 191-201. doi: 10.1016/j.annonc.2019.10.026
[18] GUISIER F, DUBOS-ARVIS C, VIÑAS F, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018[J]. J Thorac Oncol, 2020, 15(4): 628-636. doi: 10.1016/j.jtho.2019.12.129
[19] HELLMANN M D, RIZVI N A, GOLDMAN J W, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study[J]. Lancet Oncol, 2017, 18(1): 31-41.
[20] 周建娅, 周建英. 帕博利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌: KEYNOTE-021研究G队列长期生存数据[J]. 循证医学, 2021, 21(4): 208-213. https://www.cnki.com.cn/Article/CJFDTOTAL-YEBM202104005.htm [21] LEE C K, MAN J, LORD S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 210-216.
[22] GARASSINO M C, CHO B C, KIM J H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(4): 521-536. http://www.onacademic.com/detail/journal_1000040235874710_1abb.html
[23] 刘美子, 马艳. 复方苦参注射液联合阿替利珠单抗二线治疗晚期非鳞癌非小细胞肺癌的临床疗效及安全性[J]. 临床合理用药杂志, 2022, 15(18): 15-18. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202218005.htm [24] RECK M, MOK T S K, NISHIO M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiAxOGIzMTkzNzQwYjg3YWM2MmZlNTgyNjJhZGU5MWY3MRoIaWE4bDZpcDg%3D
[25] ARRIETA O, BARRÓN F, RAMÍREZ-TIRADO L A, et al. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non-small cell lung cancer: the PROLUNG phase 2 randomized clinical trial[J]. JAMA Oncol, 2020, 6(6): 856-864.
[26] LAM T C, TSANG K C, CHOI H C, et al. Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure[J]. Lung Cancer, 2021, 159: 18-26.
[27] PHARAON R, MAMBETSARIEV I, FRICKE J, et al. Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence[J]. J Thorac Dis, 2020, 12(9): 5096-5103. http://pubmed.ncbi.nlm.nih.gov/33145086/
[28] GULLEY J L, RAJAN A, SPIGEL D R, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2017, 18(5): 599-610. http://www.sciencedirect.com/science/article/pii/S1470204517302401
[29] 贾利丽, 蔺旺君. 培美曲塞加奈达铂密集化疗联合康莱特治疗肺癌疗效及对患者ERCC1、ALK水平的影响[J]. 中国药师, 2021, 24(11): 2055-2057, 2088. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYSG202111017.htm [30] SPIGEL D R, REYNOLDS C, WATERHOUSE D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370)[J]. J Thorac Oncol, 2018, 13(5): 682-688. http://www.sciencedirect.com/science/article/pii/S155608641830176X
[31] 农靖颖, 李小雪, 姚舒洋, 等. KRAS突变非小细胞肺癌的生物学和治疗研究进展[J]. 肿瘤研究与临床, 2021, 33(1): 69-73. [32] PARRA E R, VILLALOBOS P, ZHANG J X, et al. Immunohistochemical and image analysis-based study shows that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors[J]. J Thorac Oncol, 2018, 13(6): 779-791. http://www.sciencedirect.com/science/article/pii/S1556086418301825
[33] 冯会博, 谢至, 钟育敏, 等. KRAS基因不同突变亚型晚期肺腺癌的预后及PD-L1表达分析[J]. 循证医学, 2020, 20(2): 121-124. https://www.cnki.com.cn/Article/CJFDTOTAL-YEBM202002016.htm [34] LIU C M, ZHENG S F, JIN R S, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity[J]. Cancer Lett, 2020, 470: 95-105. http://www.ncbi.nlm.nih.gov/pubmed/31644929
[35] HORN L, SPIGEL D R, VOKES E E, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35): 3924-3933. http://europepmc.org/abstract/MED/29023213
[36] 彭礼秀, 韩晓, 郭珺, 等. KRAS突变晚期非小细胞肺癌患者免疫检查点抑制剂疗效观察[J]. 中华肿瘤防治杂志, 2022, 29(7): 501-507. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL202207009.htm [37] 赵媛媛, 周建英, 范云, 等. BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志, 2021, 31(12): 1145-1152. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202112001.htm [38] DUDNIK E, PELED N, NECHUSHTAN H, et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors[J]. J Thorac Oncol, 2018, 13(8): 1128-1137.
-
期刊类型引用(4)
1. 殷华芳，沙莎，蔡依玲，于波，刘佳，何佳，孙玲娣，王坚. 宫颈癌放射治疗相关卵巢损伤的分子机制及防治策略研究进展. 实用临床医药杂志. 2024(10): 141-144 . 
本站查看
2. 张玉洲，李晓敏，孙少霖. 蓝萼乙素通过Akt/BAD通路对宫颈癌裸鼠移植瘤生长的影响. 现代药物与临床. 2024(06): 1384-1389 . 百度学术
3. 沈静，张丽华，徐晶晶，吕萌萌，吴东辰. 卡瑞利珠单抗联合白蛋白结合型紫杉醇对晚期宫颈癌患者肿瘤标志物、免疫功能和血管新生指标的影响. 现代生物医学进展. 2024(13): 2592-2595 . 百度学术
4. 曾美男. 早期宫颈癌术后不同治疗方法的临床效果分析. 实用妇科内分泌电子杂志. 2023(24): 28-30+85 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 201
- HTML全文浏览量: 81
- PDF下载量: 21
- 被引次数: 4
下载:
苏公网安备 32100302010246号
